Insulatard HM SC Injection 100 IU/ml is a synthetic form of insulin used to manage blood glucose levels in people with diabetes. It is designed to mimic the natural insulin produced by the pancreas over an extended period, providing a stable and prolonged control of blood sugar levels.
Long-acting insulin is primarily used for:
| Brand Name | Insulatard HM |
|---|---|
| Type | SC Injection |
| Weight | 100 IU/ml |
| Generic | Insulin Human [Long-Acting] |
| Manufacturer | Novo Nordisk (Mfg. by: Eskayef Pharmaceuticals Ltd.) |
| Available in | English বাংলা |
Long-acting insulin works by stimulating the uptake of glucose into cells, particularly muscle and fat cells, and inhibiting glucose production in the liver. It binds to insulin receptors on cell membranes, promoting glucose transport and utilization, which helps to lower blood glucose levels.
The onset of action for long-acting insulin typically occurs within 1 to 2 hours after administration. The full therapeutic effect may take several hours to establish, and it provides a steady release of insulin over a period of 24 hours or more, depending on the specific formulation used.
Long-acting insulin is absorbed slowly from the subcutaneous tissue into the bloodstream. The rate of absorption can be influenced by factors such as injection site, blood flow, and body temperature.
Insulin is metabolized primarily in the liver and kidneys. It is broken down by insulinase and other proteolytic enzymes. The metabolites are then excreted through urine.
Dosage of long-acting insulin varies based on individual needs and blood glucose levels. Typical starting doses may range from 10 to 20 units daily, adjusted as necessary based on blood glucose monitoring. Dosage should be individualized based on the patient’s insulin sensitivity, dietary intake, and activity levels.
Long-acting insulin is administered via subcutaneous injection. Common injection sites include the abdomen, thighs, and buttocks. It is typically given once or twice daily, depending on the specific formulation and patient needs. Always follow the specific dosing instructions provided by a healthcare provider.
Common side effects include:
Rare but serious side effects may include:
Excessive dosing of long-acting insulin can lead to severe hypoglycemia, characterized by symptoms such as sweating, trembling, dizziness, and confusion. Severe cases may require medical intervention, including glucose administration or glucagon injection.
Precautions include:
Long-acting insulin can interact with various medications, including:
Use with caution in individuals with:
Drug interactions may occur with:
There are no specific food interactions, but maintaining a consistent diet helps in managing blood glucose levels effectively. Be aware of changes in diet that may require adjustments in insulin dosage.
Long-acting insulin is generally considered safe during pregnancy. However, blood glucose levels need to be carefully monitored, and insulin doses may need to be adjusted based on changes in insulin requirements during pregnancy.
Insulin use is generally considered safe during lactation. Insulin does not pass into breast milk in significant amounts, but blood glucose levels should be monitored closely to ensure proper management.
Acute overdose of long-acting insulin can result in severe hypoglycemia. Symptoms include sweating, confusion, dizziness, and loss of consciousness. Immediate treatment with oral glucose or intravenous glucose, or glucagon injection, may be required.
Long-acting insulin should be avoided in individuals with:
Follow the instructions provided by the healthcare provider or manufacturer for dosage and administration. Regular monitoring of blood glucose levels is essential for adjusting insulin dosages and maintaining optimal control.
Store insulin in the refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze. Once in use, insulin may be stored at room temperature for up to 28 days, depending on the specific product. Protect from light and heat.
The volume of distribution of long-acting insulin is not specifically documented. It is distributed throughout the extracellular fluid and binds to insulin receptors on target cells.
The half-life of long-acting insulin can vary depending on the formulation. For example, insulin glargine has a half-life of approximately 12 to 19 hours. The duration of action extends beyond the half-life due to its formulation designed for prolonged release.
Long-acting insulin is primarily cleared through hepatic and renal metabolism. The clearance rate may be influenced by factors such as liver or kidney function, as well as concurrent medications.
See in details version Insulatard HM SC Injection 100 IU/ml also Insulatard HM SC Injection 100 IU/ml in bangla